Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors

Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors

Lung cancer is frequently caused by activating mutations in the epidermal growth factor receptor (EGFR). Allosteric EGFR inhibitors offer promise as the next generation of therapeutics, as they are unaffected by common ATP-site resistance mutations and synergize with the drug osimertinib. Here, we e...

Full description

Bibliographic Details
Main Authors: Beyett, T.S (Author), De Clercq, D.J.H (Author), Eck, M.J (Author), Gomez, G. (Author), Gray, N.S (Author), Heppner, D.E (Author), Jang, J. (Author), Jänne, P.A (Author), Rana, J.K (Author), Schmoker, A.M (Author), Scott, D.A (Author), To, C. (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items